Thromboembolic Risk Factors in Patients Undergoing Kidney Transplant: Implication of Abnormally Short Activated Partial Thromboplastin Time

Annals of Clinical and Laboratory Science

Volumn 33, Issue 4, 2003, Pages 396-400

  Guirguis, Nabil G ^a   Eicher, Chad ^a   Hock, Lynette ^a   Lynch, James ^a   Graham, Vicki D ^b   Rajagopalan, P R ^b   Guirguis, Amal ^b   Lazarchick, John ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Activated partial thromboplastin time; Prothrombin time thromboembolism; Renal transplantation

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ETHNOLOGY; FEMALE; HUMAN; INCIDENCE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; DIABETES COMPLICATIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PARTIAL THROMBOPLASTIN TIME; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTHROMBIN TIME; RISK FACTORS; THROMBOEMBOLISM;

EID: 0142089082     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bakir N, Sluiter WJ, Ploeg RJ, van Son WJ, Tegzess AM. Primary renal graft thrombosis. Nephrol Dial Transplant 1996;11:140-147.
2. Oh J, Schaefer F, Veldmann A, Nowak G, Nowak-Gottl U, Tonshoff B, et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999;68:575-578.
3. Ekberg H, Svensson PJ, Simanaitis M, Dahlback B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000;69: 1577-1581.
4. Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, Dunn DL, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998;65:229-234.
5. Arnadottir M, Bergentz SE, Bergqvist D, Husberg B, Konrad P, Lindholm T. Thromboembolic complications after renal transplantation: a retrospective analysis. World J Surg 1983;7:757-761.
6. Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997;64:604-607.
7. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
8. Vaidya S, Wang CC, Gugliuzza C, Fish JC. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998;12: 439-444.
9. Knight RJ, Schanzer H, Rand JH, Burrows L. Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Transplantation 1995;60:614-61.
10. Wagenknecht DR, Fastenau DR, Torry RJ, Carter CB, Haag BW, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft. Transplant Proc 1999;31:285-288.
11. Wang Y, Turner N, An SF, Fleming KA, Thompson EM. Gene expression of plasminogen activator inhibitor 1 in transplant kidneys complicated by renal vein thrombosis: a combined study by in-situ hybridization and immunohistochemistry. Nephrol Dial Transplant 1994;9:296-303.
12. Penny MJ, Nankivell BJ, Disney AP, Byth K, Chapman JR. Renal graft thrombosis. A survey of 134 consecutive cases. Transplantation 1994;58:565-569.
13. Toulon P, Moulonguet-Doleris L, Costa JM, Aiach M. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemost 1991;65:20-24.
14. Guirguis N, Budisavljevic MN, Self S, Rajagopalan PR, Lazarchick J. Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation. Ann Clin Lab Sci 2000;30:75-78.
15. Ojo AO, Hanson JA, Wolfe RA, Agodoa LY, Leavey SF, Leichtman A, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999;55:1952-1960.
16. Heidenreich S, Dercken C, August C, Koch HG, Nowak-Gottl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998;9:1309-1313.
17. McKenna R, Bachmann F, Miro-Quesada M. Thromboembolism in patients with abnormally short activated partial thromboplastin time. Thromb Haemost 1977;38: 893-899.
18. Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70:463-470.
19. Landi G, D'Angelo A, Boccardi E, Candelise L, Mannucci PM, Morabito A, et al. Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. Arch Neurol 1992;49:279-283.
20. Gallus AS, Hirsh J, Gent M. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet 1973;2:805-809.
21. Belliveau RR. Extremely shortened activated partial thromboplastin times. JAMA 1980;243:2286.
22. Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000;113:123-127.